Dechra Launches Domidine Equine Sedative in the US
Quick Takeaways:
- Dechra has launched Domidine (detomidine hydrochloride) in the US, expanding access to an equine sedative and analgesic used to facilitate minor surgical and diagnostic procedures in horses.
- Domidine has been used internationally for more than a decade, with over 7 million doses administered globally since 2016. The generic detomidine product is designed to provide predictable sedation and can be integrated into existing veterinary protocols.
- The launch gives US equine veterinarians a cost-effective detomidine option, supporting clinical flexibility while helping practices manage treatment costs. Dechra said Domidine complements its broader portfolio of equine sedation solutions and supports veterinarians in delivering consistent patient care.
Why It Matters?
Dechra’s US launch of Domidine (detomidine) adds a generic, cost‑effective alpha‑2 agonist to the equine sedation market, giving veterinarians a familiar, predictable option for minor surgical and diagnostic procedures while helping practices manage drug spend. With >10 years of international use and millions of doses administered, Domidine can quickly slot into existing protocols and strengthen Dechra’s equine portfolio, potentially increasing share in a competitive sedation category where price and reliability drive switching.
Source: Businesswire
